Amarin reported $164.2M in Current Liabilities for its fiscal quarter ending in June of 2026.





Current Liabilities Change Date
AbbVie USD 41.64B 458M Jun/2026
Alnylam Pharmaceuticals USD 1.51B 163.04M Jun/2026
Amarin USD 164.2M 15.45M Jun/2026
AstraZeneca USD 31.55B 1.02B Jun/2026
BioCryst Pharmaceuticals USD 195.39M 675K Mar/2026
DBV Technologies USD 54.3M 2.5M Jun/2026
GlaxoSmithKline GBP 21.53B 895M Jun/2026
Halozyme Therapeutics USD 363.21M 186.12M Mar/2026
Heron Therapeutics USD 90.52M 5.58M Mar/2026
Ionis Pharmaceuticals USD 315.64M 401.36M Jun/2026
Nektar Therapeutics USD 57.71M 4.17M Mar/2026
Neurocrine Biosciences USD 874.5M 42.8M Jun/2026
Novartis USD 31.75B 374M Jun/2026